Abstract
Significant expression of neprilysin (NEP) is found on neutrophils, which present the transmembrane integer form of the enzyme. This study aimed to investigate the relationship of neutrophil transmembrane neprilysin (mNEP) with disease severity, adverse remodeling, and outcome in HFrEF. In total, 228 HFrEF, 30 HFpEF patients, and 43 controls were enrolled. Neutrophil mNEP was measured by flow-cytometry. NEP activity in plasma and blood cells was determined for a subset of HFrEF patients using mass-spectrometry. Heart failure (HF) was characterized by reduced neutrophil mNEP compared to controls (p < 0.01). NEP activity on peripheral blood cells was almost 4-fold higher compared to plasma NEP activity (p = 0.031) and correlated with neutrophil mNEP (p = 0.006). Lower neutrophil mNEP was associated with increasing disease severity and markers of adverse remodeling. Higher neutrophil mNEP was associated with reduced risk for mortality, total cardiovascular hospitalizations, and the composite endpoint of both (p < 0.01 for all). This is the first report describing a significant role of neutrophil mNEP in HFrEF. The biological relevance of neutrophil mNEP and exact effects of angiotensin-converting-enzyme inhibitors (ARNi) at the neutrophil site have to be determined. However, the results may suggest early initiation of ARNi already in less severe HF disease, where effects of NEP inhibition may be more pronounced.
Highlights
IntroductionThe landmark PARADIGM-Heart failure (HF) trial has impressively demonstrated that combined inhibition of the angiotensin II type 1 receptor and neprilysin (NEP) results in significant improved outcomes in patients with chronic heart failure with reduced ejection fraction (HFrEF) [1]
The landmark PARADIGM-Heart failure (HF) trial has impressively demonstrated that combined inhibition of the angiotensin II type 1 receptor and neprilysin (NEP) results in significant improved outcomes in patients with chronic heart failure with reduced ejection fraction (HFrEF) [1].Data from the relatively recent PARAGON-HF study imply that individuals with heart failure (HF) with mildly-to-moderately reduced left ventricular function and distinct subgroups of patients with preserved ejection fraction may benefit from sacubitril/valsartan therapy [2]
A total of 228 HFrEF patients were included in the study
Summary
The landmark PARADIGM-HF trial has impressively demonstrated that combined inhibition of the angiotensin II type 1 receptor and neprilysin (NEP) results in significant improved outcomes in patients with chronic heart failure with reduced ejection fraction (HFrEF) [1]. Data from the relatively recent PARAGON-HF study imply that individuals with heart failure (HF) with mildly-to-moderately reduced left ventricular function and distinct subgroups of patients with preserved ejection fraction may benefit from sacubitril/valsartan therapy [2]. NEP, known as cluster of differentiation 10 (CD10), neutral endopeptidase, enkephalinase, or common acute lymphoblastic leukemia antigen, is a zinc-dependent transmembrane metalloendoprotease that is involved in the breakdown of a plethora of vasoactive peptides, including natriuretic peptides, adrenomedullin, angiotensin II, and endothelin-1 [4,5,6]. NEP is found in the plasma membrane of cells in the kidneys, lungs, intestine, brain, and liver and has been shown to be identical to CD10, which is expressed on several distinct hematopoietic cell lineages including neutrophils [4,7]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have